title: The feasibility of establishing a programme of adjuvant autologous vaccination for renal cell carcinoma.
abstract: OBJECTIVE
  To report the results of a programme aimed at determining the feasibility of autologous renal cell carcinoma (RCC) tissue collection and vaccine preparation within the setting of a UK National Health Service Cancer Centre.
  
  
  METHODS
  Patients undergoing nephrectomy for suspected renal tumours were identified from theatre lists between April 2005 and July 2007. Samples of tumour were freshly cut from nephrectomy specimens. If tissue collection failed the reason was recorded prospectively. Cell viability was assessed after sample sieving. Freeze-thaw lysates were prepared from viable tumour cells, and the immunogenicity tested by pulsing onto dendritic cells (DC).
  
  
  RESULTS
  Of 84 patients, 83 had a histological diagnosis of RCC; samples were obtained from 29 of these 83 (35%). Reasons for failure in tissue collection included that the tumour was too small or haemorrhagic/necrotic, pre-surgical embolization, and difficulties with fresh tumour collection out of normal working hours. Viable tumour cells were obtained in 12 of the 29 samples (41%); no factor was able to predict the production of viable cells. Unmodified lysates did not activate DC.
  
  
  CONCLUSIONS
  An autologous RCC vaccination programme might fail to generate vaccines for a substantial proportion of eligible patients in the setting of a clinical cancer centre.
authors.affiliation: Cancer research UK Clinical Centre, Leeds Institute of Molecular Medicine, University of Leeds, Leeds, UK.
authors.forename: Robin J
authors.initials: RJ
authors.lastname: Prestwich
authors.forename: Karen J
authors.initials: KJ
authors.lastname: Scott
authors.forename: Joanne
authors.initials: J
authors.lastname: Brown
authors.forename: Patricia
authors.initials: P
authors.lastname: Harnden
authors.forename: Peter
authors.initials: P
authors.lastname: Whelan
authors.forename: Jon
authors.initials: J
authors.lastname: Cartledge
authors.forename: Dearbhaile
authors.initials: D
authors.lastname: O'Donnell
authors.forename: Hardev S
authors.initials: HS
authors.lastname: Pandha
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Selby
authors.forename: Rosamund E
authors.initials: RE
authors.lastname: Banks
authors.forename: Alison E
authors.initials: AE
authors.lastname: Merrick
authors.forename: Alan A
authors.initials: AA
authors.lastname: Melcher
mesh_terms: D000276:Adjuvants, Immunologic; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D019496:Cancer Vaccines; D002292:Carcinoma, Renal Cell / Q000517:prevention & control*; D003713:Dendritic Cells / Q000637:transplantation; D004797:Enzyme-Linked Immunosorbent Assay; D004812:Epidemiologic Methods; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D016753:Interleukin-10 / Q000378:metabolism; D018664:Interleukin-12 / Q000378:metabolism; D007680:Kidney Neoplasms / Q000517:prevention & control*; D008297:Male; D008875:Middle Aged; D009392:Nephrectomy; D015397:Program Evaluation; D014015:Tissue Banks
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D016753:Interleukin-10; D018664:Interleukin-12